Cargando…
Efficacy of a Parainfluenza Virus 5 (PIV5)-Based H7N9 Vaccine in Mice and Guinea Pigs: Antibody Titer towards HA Was Not a Good Indicator for Protection
H7N9 has caused fatal infections in humans. A safe and effective vaccine is the best way to prevent large-scale outbreaks in the human population. Parainfluenza virus 5 (PIV5), an avirulent paramyxovirus, is a promising vaccine vector. In this work, we generated a recombinant PIV5 expressing the HA...
Autores principales: | Li, Zhuo, Gabbard, Jon D., Johnson, Scott, Dlugolenski, Daniel, Phan, Shannon, Tompkins, S. Mark, He, Biao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4372596/ https://www.ncbi.nlm.nih.gov/pubmed/25803697 http://dx.doi.org/10.1371/journal.pone.0120355 |
Ejemplares similares
-
Structure of the Parainfluenza Virus 5 (PIV5) Hemagglutinin-Neuraminidase (HN) Ectodomain
por: Welch, Brett D., et al.
Publicado: (2013) -
Efficacy of Parainfluenza Virus 5 (PIV5)-vectored Intranasal COVID-19 Vaccine as a Single Dose Vaccine and as a Booster against SARS-CoV-2 Variants
por: Beavis, Ashley C., et al.
Publicado: (2022) -
Intranasal parainfluenza virus type 5 (PIV5)–vectored RSV vaccine is safe and immunogenic in healthy adults in a phase 1 clinical study
por: Spearman, Paul, et al.
Publicado: (2023) -
A parainfluenza virus 5 (PIV5)-vectored intranasal vaccine for Lyme disease provides long-lasting protection against tick transmitted Borrelia burgdorferi in mice
por: Gingerich, Maria Cristina, et al.
Publicado: (2023) -
1104. Characteristics and Seasonality of Children Hospitalized with Parainfluenza Virus Infections (PIV), including PIV-4, New Vaccine Surveillance Network, 2016–2020
por: de St. Maurice, Annabelle M, et al.
Publicado: (2023)